IQVIA Biotech’s Sockalingam On Clinical Research Virtualization In APAC
Executive Summary
In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.
Dr Senthil Sockalingam, head, IQVIA Biotech, Japan-Asia Pacific (JAPAC) and chief medical officer, APAC, spoke to Scrip on trends and opportunities in the clinical research segment, partnering/outsourcing approaches and digitalization efficiencies, driven by the pandemic.
Rapid "virtualization" of the trials segment, how the regulatory framework in certain APAC markets is still catching up in this area, and adoption of telemedicine are some of the other key issues he delves into in this audio interview.
Sockalingam, a physician by training, also declared that artificial intelligence is the “new stethoscope or echocardiogram” and will only aid - not replace - doctors. There’s no need for them to become “nervous” he said.
Podcast Time Stamps
00:08 Introduction
00:58 IQVIA Biotech’s Latest Expansion In Japan/Asia Pacific
04:40 Diverse APAC Region, Oncology/Immunology Focus Of Biotechs, Partnering Models
11.53 Pandemic-Driven Virtualization Of Trials, Site Contracting Timelines
17:57 Digital Launch Efforts, Democratization Of Healthcare Providers’ Access To Information
21:25 Evolving Patient Journey
24:16 AI In Drug Development,Treatment
These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Related Stories:
https://scrip.pharmaintelligence.informa.com/SC144238/ISCRs-Davis-On-Pandemic-Adaptations-Value-Of-MultiRegional-Trials